Research field (1)：
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (4)：
2021 - 2022 A phase II study of alectinib for newly diagnosed ALK-positive anaplastic large cell lymphoma common type (protocol development)
2016 - 2021 A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastoma
2003 - 2005 未分化大細胞性リンパ腫細胞の増殖・細胞死に関与する因子の解析
2001 - 2002 バーキットリンパ腫細胞の糖脂質膜ドメインを介するアポトーシス誘導機構の解析
Papers (71)：
Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M Saito, et al. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial. European journal of haematology. 2023
Junichi Hara, Chika Nitani, Hiroyuki Shichino, Tatsuo Kuroda, Tomoro Hishiki, Toshinori Soejima, Tetsuya Mori, Kimikazu Matsumoto, Yoji Sasahara, Tomoko Iehara, et al. Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation. Japanese Journal of Clinical Oncology. 2022. 52. 5. 486-492
